To include your compound in the COVID-19 Resource Center, submit it here.

Amgen gains on additional Xgeva data

Amgen Inc. (NASDAQ:AMGN) gained $1.03 to $60.89 on Tuesday after reporting additional data from two Phase III trials of Xgeva denosumab at the American Urological Association meeting

Read the full 275 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE